SpringWorks Therapeutics (SWTX) Jefferies London Healthcare Conference 2024 summary

Business overview and product portfolio

• One approved product for desmoid tumors, launched about a year ago, is the first and only approved treatment for adults with this condition.

• The company is confident in the market size, position, and durability of its desmoid tumor opportunity.

• Next program targets NF1-PN, with a PDUFA date of February 28 and data expected to be best-in-class for children and first-in-class for adults.

• Both lead programs are considered to have over $1 billion potential in the U.S. alone.

• Additional earlier-stage programs are in the pipeline, but focus remains on the two advanced assets.

Market opportunity and commercial execution

• ICD-10 claims for desmoid tumors exceeded 10,000 in less than a year, indicating a larger market than previously estimated.

• Over 90% of diagnosed patients are expected to be treated, with strong physician and patient enthusiasm.

• Ogsivio has achieved 70% market share of new prescriptions and is now the systemic standard of care.

• Median treatment duration is at least three years, with continued benefit and high adherence.

• Price is set at $29,000/month, with 95%+ insurance coverage and less than 10% market penetration so far.

Financial performance and growth trajectory

• Achieved $50 million in revenue last quarter, with a projected annualized run rate of $200 million.

• Patient base is steadily growing, with the largest revenue months occurring consecutively.

• Growth is expected to continue as more patients are added and remain on therapy for extended periods.